Suspected opioid overdose case resolved by CYP2D6 genotyping

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 121-123

  Shaw, Kaitlyn D ^a,b,c,d   Amstutz, Ursula ^a,b,c,d   Jimenez Mendez, Ricardo ^a,b,c,d   Ross, Colin J D ^a,c,d   Carleton, Bruce C ^a,b,c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BC CHILDREN S HOSPITAL   (Canada)

^c Canadian Pharmacogenomics Network for Drug Safety   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CYP2D6; opioids; pharmacogenetics

Indexed keywords

CAFFEINE; CAFFEINE PLUS CODEINE PLUS PARACETAMOL; COCODAMOL; CODEINE; CYTOCHROME P450 2D6; DRUG METABOLITE; MORPHINE; NALOXONE; OPIATE; TYLENOL 3; UNCLASSIFIED DRUG;

ADOLESCENT; ANALGESIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; CASE REPORT; DISEASE COURSE; DROWSINESS; DRUG EFFECT; DRUG OVERDOSE; DRUG TRANSFORMATION; FEMALE; GENOTYPE; HIP PAIN; HUMAN; IRRITABILITY; MORNING DOSAGE; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ACETAMINOPHEN; ADOLESCENT; ANALGESICS, OPIOID; CAFFEINE; CODEINE; CYTOCHROME P-450 CYP2D6; DRUG COMBINATIONS; FEMALE; GENOTYPE; HUMANS; OVERDOSE; PAIN; PHARMACOGENETICS;

EID: 84858707072     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824a1e21     Document Type: Article

References (25)

1. Dayer P, Desmeules J, Leemann T, et al. Bioactivation of the narcotic drug codeine in human-liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome-P-450 Dbl/Bufi). Biochem Biophys Res Commun. 1988;152:411-416.
2. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet. 1988;2:914-915.
3. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-242.
4. vanderVaart S, Berger H, Sistonen J, et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monitor. 2011;33:425-432.
5. Gaedigk A, Ndjountche L, Divakaran K, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther. 2007;81:242-251. (Pubitemid 46178274)
6. Koren G, Cairns J, Chitayak D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704. (Pubitemid 44223697)
7. Madadi P, Ross CJD, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009;85:31-35.
8. Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapidmetabolism genotype, and postoperative death. N Engl J Med. 2009;361: 827-828.
9. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome-P450 Cyp2d locus. Nature. 1990;347: 773-776.
10. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated Cyp2d6(D) gene deletion allele by long-Pcr technology. Pharmacogenetics. 1995;5:215-223.
11. La Vincente SF, White JM, Somogyi AA, et al. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clin Pharmacol Ther. 2008;83:144-152.
12. Gear RW, Miaskowski C, Gordon NC, et al. Action of naloxone on gender-dependent analgesic and antianalgesic effects of nalbuphine in humans. J Pain. 2000;1:122-127. (Pubitemid 30640010)
13. Cruciani RA, Lussier D, Miller-Saultz D, et al. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage. 2003;25:491-494. (Pubitemid 36629270)
14. Schmidt BL, Gear RW, Levine JD. Response of neuropathic trigeminal pain to the combination of low-dose nalbuphine plus naloxone in humans. Neurosci Lett. 2003;343:144-146. (Pubitemid 36577535)
15. Cepeda MS, Alvarez H, Morales O, et al. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain. 2004;107:41-46. (Pubitemid 38058697)
16. Dagli AI, Williams CA. Angelman syndrome. In: Pagon RA, Bird TD, Dolan CR, et al, eds. GeneReviews. Seattle, WA: University of Washington; 1993-2011. Available at http://genetests.org. Accessed October 1, 2011.
17. Galanopoulou AS. Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010;460:505-523.
18. Pelc K, Boyd SG, Cheron G, et al. Epilepsy in Angelman syndrome. Seizure. 2008;17:211-217. (Pubitemid 351324161)
19. Pelc K, Cheron G, Boyd SG, et al. Are there distinctive sleep problems in Angelman syndrome? Sleep Med. 2008;9:434-441. (Pubitemid 351664084)
20. Fiumara A, Pittala A, Cocuzza M, et al. Epilepsy in patients with Angelman syndrome. Ital J Pediatr. 2010;36:31.
21. Breuker E, Dingledine R, Iversen LL. Evidence for naloxone and opiates as gaba antagonists. Br J Pharmacol. 1976;58:P458.
22. Dingledine R, Iversen LL, Breuker E. Naloxone as a Gaba antagonist-evidence from Iontophoretic, receptor-binding and convulsant studies. Eur J Pharmacol. 1978;47:19-27. (Pubitemid 8244114)
23. Zwisler ST, Enggaard TP, Noehr-Jensen L, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol. 2009; 104:335-344.
24. Smith HS. The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain. 2011;27:824-838.
25. Smith HS. Opioid metabolism. Mayo Clinic Proc. 2009;84:613-624.